Collegium Pharmaceutical's (NASDAQ: COLL) stock soared 7.32% in the after-hours trading session on Thursday, following the company's impressive fourth-quarter earnings report.
The pharmaceutical firm reported quarterly adjusted earnings of $1.75 per share, beating analysts' consensus estimate of $1.54 by a significant margin of 13.64%. The company's revenue also surpassed expectations, coming in at $181.95 million, which is 1.20% higher than the forecasted $179.79 million. Compared to the same period last year, Collegium Pharmaceutical's earnings and sales grew by 10.76% and 21.51%, respectively.
The strong financial performance and better-than-expected results are likely the key factors driving the after-hours surge in Collegium Pharmaceutical's stock price. Investors appear to be reacting positively to the company's ability to deliver solid growth and exceed analysts' estimates.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。